Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Wiley full text link Wiley Free PMC article
Full text links

Actions

Meta-Analysis
.2015 Jan 28;1(1):CD010632.
doi: 10.1002/14651858.CD010632.pub2.

¹⁸F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)

Affiliations
Meta-Analysis

¹⁸F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)

Nadja Smailagic et al. Cochrane Database Syst Rev..

Abstract

Background: ¹⁸F-FDFG uptake by brain tissue as measured by positron emission tomography (PET) is a well-established method for assessment of brain function in people with dementia. Certain findings on brain PET scans can potentially predict the decline of mild cognitive Impairment (MCI) to Alzheimer's disease dementia or other dementias.

Objectives: To determine the diagnostic accuracy of the ¹⁸F-FDG PET index test for detecting people with MCI at baseline who would clinically convert to Alzheimer's disease dementia or other forms of dementia at follow-up.

Search methods: We searched the Cochrane Register of Diagnostic Test Accuracy Studies, MEDLINE, EMBASE, Science Citation Index, PsycINFO, BIOSIS previews, LILACS, MEDION, (Meta-analyses van Diagnostisch Onderzoek), DARE (Database of Abstracts of Reviews of Effects), HTA (Health Technology Assessment Database), ARIF (Aggressive Research Intelligence Facility) and C-EBLM (International Federation of Clinical Chemistry and Laboratory Medicine Committee for Evidence-based Laboratory Medicine) databases to January 2013. We checked the reference lists of any relevant studies and systematic reviews for additional studies.

Selection criteria: We included studies that evaluated the diagnostic accuracy of ¹⁸F-FDG PET to determine the conversion from MCI to Alzheimer's disease dementia or to other forms of dementia, i.e. any or all of vascular dementia, dementia with Lewy bodies, and fronto-temporal dementia. These studies necessarily employ delayed verification of conversion to dementia and are sometimes labelled as 'delayed verification cross-sectional studies'.

Data collection and analysis: Two blinded review authors independently extracted data, resolving disagreement by discussion, with the option to involve a third review author as arbiter if necessary. We extracted and summarised graphically the data for two-by-two tables. We conducted exploratory analyses by plotting estimates of sensitivity and specificity from each study on forest plots and in receiver operating characteristic (ROC) space. When studies had mixed thresholds, we derived estimates of sensitivity and likelihood ratios at fixed values (lower quartile, median and upper quartile) of specificity from the hierarchical summary ROC (HSROC) models.

Main results: We included 14 studies (421 participants) in the analysis. The sensitivities for conversion from MCI to Alzheimer's disease dementia were between 25% and 100% while the specificities were between 15% and 100%. From the summary ROC curve we fitted we estimated that the sensitivity was 76% (95% confidence interval (CI): 53.8 to 89.7) at the included study median specificity of 82%. This equates to a positive likelihood ratio of 4.03 (95% CI: 2.97 to 5.47), and a negative likelihood ratio of 0.34 (95% CI: 0.15 to 0.75). Three studies recruited participants from the same Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort but only the largest ADNI study (Herholz 2011) is included in the meta-analysis. In order to demonstrate whether the choice of ADNI study or discriminating brain region (Chételat 2003) or reader assessment (Pardo 2010) make a difference to the pooled estimate, we performed five additional analyses. At the median specificity of 82%, the estimated sensitivity was between 74% and 76%. There was no impact on our findings. In addition to evaluating Alzheimer's disease dementia, five studies evaluated the accuracy of ¹⁸F-FDG PET for all types of dementia. The sensitivities were between 46% and 95% while the specificities were between 29% and 100%; however, we did not conduct a meta-analysis because of too few studies, and those studies which we had found recruited small numbers of participants. Our findings are based on studies with poor reporting, and the majority of included studies had an unclear risk of bias, mainly for the reference standard and participant selection domains. According to the assessment of Index test domain, more than 50% of studies were of poor methodological quality.

Authors' conclusions: It is difficult to determine to what extent the findings from the meta-analysis can be applied to clinical practice. Given the considerable variability of specificity values and lack of defined thresholds for determination of test positivity in the included studies, the current evidence does not support the routine use of ¹⁸F-FDG PET scans in clinical practice in people with MCI. The ¹⁸F-FDG PET scan is a high-cost investigation, and it is therefore important to clearly demonstrate its accuracy and to standardise the process of ¹⁸F-FDG PET diagnostic modality prior to its being widely used. Future studies with more uniform approaches to thresholds, analysis and study conduct may provide a more homogeneous estimate than the one available from the included studies we have identified.

PubMed Disclaimer

Conflict of interest statement

NS, MV, CH, SM, OU, CS: declare no conflict of interest.

Figures

1
1
Study flow diagram.
2
2
Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study
3
3
Risk of bias and applicability concerns graph: review authors' judgements about each domain presented as percentages across included studies
4
4
Forest plot of ¹⁸F‐FDG PET Conversion from MCI to AD (with Reader 1 Pardo 2010, Chetelat 2003 temporo‐parietal region and Herholz 2011 ADNI study).
5
5
Summary ROC plot of ¹⁸F‐FDG PET Conversion from MCI to AD (with Reader 1 Pardo 2010, Chetelat 2003 temporo‐parietal region and Herholz 2011 ADNI study).
6
6
Forest plot of ¹⁸F‐FDG PET Conversion from MCI to All dementia (with Reader 1 Pardo 2010).
7
7
Summary ROC plot of ¹⁸F‐FDG PET Conversion from MCI to All dementia (with Reader 1 Pardo 2010).
1
1. Test
18FFDG‐PET Conversion from MCI to AD (with Reader 1 Pardo 2010, Chetelat 2003 temporo‐parietal region and Herholz 2011 ADNI study).
2
2. Test
18FFDG‐PET Conversion from MCI to AD (with Reader 1 Pardo 2010, Chetelat 2003 temporo‐parietal region and Landau 2010 ADNI study).
3
3. Test
18FFDG‐PET Conversion from MCI to AD (with Reader 1 Pardo 2010, Chetelat 2003 temporo‐parietal region and Schmand 2012 ADNI study).
4
4. Test
18FFDG‐PET Conversion from MCI to AD (with Reader 1 Pardo 2010, Chetelat 2003 posterior cingulate region and Herholz 2011 ADNI study).
5
5. Test
18FFDG‐PET Conversion from MCI to AD (with Reader 2 Pardo 2010, Chetelat 2003 temporo‐parietal region and Herholz 2011 ADNI study).
6
6. Test
18FFDG‐PET Conversion from MCI to AD (with Reader 2 Pardo 2010, Chetelat 2003 posterior cingulate region and Herholz 2011 ADNI study).
7
7. Test
18FFDG‐PET Conversion from MCI to All dementia (with Reader 1 Pardo 2010).
8
8. Test
18FFDG‐PET Conversion from MCI to All dementia (with Reader 2 Pardo 2010).
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Anchisi 2005 {published data only}
    1. Anchisi D, Borroni B, Franceschi M, Kerrouche N, Kalbe E, Kerrouche N, at al. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Archives of Neurology 2005;62(11):1728‐33. - PubMed
Arnáiz 2001 {published data only}
    1. Arnáiz E, Jelic V, Almkvist O, Wahlund L‐O, Winbald B, Valind S, et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport 2001;12(4):851‐5. - PubMed
Berent 1999 {published data only}
    1. Berent S, Giordani B, Foster N, Minoshima S, Lajiness‐O'Neill R, Koeppe R, et al. Neuropsychological function and cerebral glucose utilization in isolated memory impairment and Alzheimer's disease. Journal of Psychiatric Research 1999;33(1):7‐16. - PubMed
Chételat 2003 {published data only}
    1. Chételat G, Desgranges B, Sayette V, Viadre F, Eustache F, Baron JC. Mild cognitive impairment: can FDG‐PET predict who is to rapidly convert to Alzheimer's disease?. Neurology 2003;60(8):1374‐7. - PubMed
Clerici 2009 {published data only}
    1. Clerici F. Differences in hippocampal metabolism between amnestic and non‐amnestic MCI subjects: automated FDG‐PET image analysis. Quarterly Journal of Nuclear Medicine and Molecular Imaging 2009;53(6):646‐57. - PubMed
Drzezga 2005 {published data only}
    1. Drzezga A, Grimmer T, Rimenschneider M, Lautenschlager N, Siebner H, Alexopoulus, et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F‐FDG PET. Journal of Nuclear Medicine 2005;46(10):1625‐32. - PubMed
Fellgiebel 2007 {published data only}
    1. Fellgiebel A, Scheurich A, Bartenstein P, Müller MJ. FDG‐PET and CSF phospho‐tau for prediction of cognitive decline in mild cognitive impairment. Psychiatry Research 2007;155(2):167‐71. - PubMed
Galluzzi 2010 {published data only}
    1. Galluzzi S, Geroldi, C, Ghidoni R, Paghera B, Amicucci B, Bonetti M, et al. The new Alzheimer’s criteria in a naturalistic series of patients with mild cognitive impairment. Journal of Neurology 2010;257(12):2004–14. - PubMed
Herholz 2011 {published data only}
    1. Herholz K, Westwood S, Haense C, Dunn G. Evaluation of a calibrated (18)F‐FDG PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment. Journal of Nuclear Medicine 2011;52(8):1218‐26. - PubMed
Landau 2010 {published data only}
    1. Landau SM, Harvey D, Madison CM, Reiman EM, Foster NL, Aisen PS, et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 2010;75(3):230‐8. - PMC - PubMed
Mosconi 2004 {published data only}
    1. Mosconi L, Perani D, Sorbi S, Herholz K, Nacmias B, Holthoff V, et al. MCI conversion to dementia and APOE genotype: a prediction study with FDG‐PET. Neurology 2004;63(12):2332‐40. - PubMed
Nobili 2008 {published data only}
    1. Nobili F, Salmaso D, Morbelli S, Girtler N, Piccardo A, Brugnolo A, et al. Principal component analysis of FDG PET in amnestic MCI. European Journal of Nuclear Medicine and Molecular Imaging 2008;35(12):2191‐202. - PubMed
Ossenkoppele 2012a {published data only}
    1. Ossenkoppele R, Tolboom N, Foster‐Dingley JC, Adriaanse SF, Boellaard R, Yaqub M, et al. Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. European Journal of Nuclear Medicine and Molecular Imaging 2012;39(6):990‐1000. - PubMed
Ossenkoppele 2012b {published data only}
    1. Ossenkoppele R, Prins N, Pijnenburg YAL, Lemstra AW, Flier WM, Adriaanse SF, et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimer's & Dementia 2012;9(4):414‐21. - PubMed
Pardo 2010 {published data only}
    1. Pardo JV, Lee JT, Kuskowski MA, Munch KR, Carlis JV, Sheikh SA, et al. Fluorodeoxiglucose positron emission tomography of mild cognitive impairment with clinical follow‐up at 3 years. Alzheimer's & Dementia 2010;6(4):326‐33. - PMC - PubMed
Schmand 2012 {published data only}
    1. Schmand B, Eikelenboom P, Gool WA, Alzheimer's Disease Neuroimaging Initiative. Value of diagnostic tests to predict conversion to Alzheimer’s Disease in young and old patients with amnestic mild cognitive impairment. Journal of Alzheimer's Disease 2012;29(3):641‐8. - PubMed

References to studies excluded from this review

Bastin 2010 {published data only}
    1. Bastin C, Kerrouche N, Lekeu F, Adam S, Guillame B, Lemaire C, et al. Controlled memory processes in questionable Alzheimer's disease: A view from neuroimaging research. Journal of Alzheimer's Disease 2010; Vol. 20, issue 2:547‐60. - PubMed
Beckett 2010 {published data only}
    1. Beckett LA, Harvey DJ, Gamst A, Donohue M, Kornak J, Zhang H, et al. The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes. Alzheimer's & Dementia 2010; Vol. 6, issue 3:257‐64. [1552‐5260] - PMC - PubMed
Charil 2011 {published data only}
    1. Charil A, Carbonell F, Reilhac A, Deduck K, Sood R, Evans A. Changes in MRI cortical thickness and [18F]FDG PET data over 24 months in subjects from the Alzheimer's disease neuroimaging initiative (ADNI) study. Alzheimer's and Dementia Conference: Alzheimer's Association International Conference, AAIC 11 Paris France. Conference Publication. 2011.
Chen 2010 {published data only}
    1. Chen K, Langbaum JB, Fleisher AS, Ayutyanont N, Reschke C, Lee W, et al. Twelve‐month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre‐defined statistical region‐of‐interest: findings from the Alzheimer's Disease Neuroimaging Initiative. NeuroImage 2010; Vol. 51, issue 2:654‐64. [1053‐8119] - PMC - PubMed
Chételat 2001 {published data only}
    1. Chételat G, Desgranges B, Sayette V, Lalevee C, Landeau B, Dupuy B. Metabolic profile of patients with mild cognitive impairment (MCI) destined to convert to Alzheimer's disease (AD). Society for Neuroscience Abstracts 2001;27(1):196.
Chételat 2005 {published data only}
    1. Chételat G, Eustache F, Viader F, Sayette V, Pélerin A, Mézenge F, et al. FDG‐PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment. Neurocase 2005; Vol. 11, issue 1:14‐25. - PubMed
Desikan 2010 {published data only}
    1. Desikan RS, Cabral HJ, Settecase F, Hess CP, Dillon WP, Glastonbury CM, et al. Automated MRI measures predict progression to Alzheimer's disease. Neurobiology of Aging 2010; Vol. 31, issue 8:1364‐74. - PMC - PubMed
Drzezga 2003 {published data only}
    1. Drzezga A, Lautenschlager N, Siebner H, Reimenschneider M, Willoch F, Minoshima S, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow‐up study. European Journal of Nuclear Medicine and Molecular Imaging 2003;30(8):1104‐13. - PubMed
Forsberg 2008 {published data only}
    1. Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiology of Aging 2008; Vol. 29, issue 10:1456‐65. - PubMed
Garibotto 2008 {published data only}
    1. Garibotto V, Borroni B, Kalbe E, Herholz K, Salmon E, Holtoff V, et al. Education and occupation as proxies for reserve in aMCI converters and AD FDG‐PET evidence. Neurology 2008;71(17):1342‐9. - PubMed
Gray 2012 {published data only}
    1. Gray KR, Wolz R, Heckemann RA, Aljabar P, Hammers A, Rueckert D. Multi‐region analysis of longitudinal FDG‐PET for the classification of Alzheimer's disease. NeuroImage 2012;60(1):221‐9. - PMC - PubMed
Hunt 2007 {published data only}
    1. Hunt A, Schönknecht P, Henze M, Seidl U, Haberkorn U, Schröder J. Reduced cerebral glucose metabolism in patients at risk for Alzheimer's disease. Psychiatry Research 2007;155(2):147‐54. - PubMed
Ishii 2009 {published data only}
    1. Ishii H, Ishikawa H, Meguro K, Tashiro M, Yamaguchi S. Decreased cortical glucose metabolism in converters from CDR 0.5 to Alzheimer's disease in a community: the Osaki‐Tajiri Project. International Psychogeriatrics 2009;21(1):148‐56. - PubMed
Ishii 2011 {published data only}
    1. Ishii K, Ito K, Senda M, Kato T, Fukuyama H, Ouchi Y, Meguro K, et al. SEAD‐J Group. FDG‐PET and automatic diagnosis systems for prediction of conversion to Alzheimer disease in subjects with mild cognitive impairments: Study on diagnosis of early Alzheimer disease‐Japan (SEAD‐J). Annual Congress of the European Association of Nuclear Medicine, Birmingham. Conference Publication. 2011.
Jagust 2007 {published data only}
    1. Jagust W, Reed B, Mungas D, Ellis W, Decarli C. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?. Neurology 2007;69(9):871‐7. - PubMed
Kadir 2012 {published data only}
    1. Kadir A, Almkvist O, Forsberg A, Wall A, Engler H, Langstrom B, Nordberg A. Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease. Neurobiology of Aging 2012;33(1):198.e1‐14. - PubMed
Kawashima 2012 {published data only}
    1. Kawashima S, Ito K, Kato T, SEAD‐J Study Group. Inclusion criteria provide heterogeneity in baseline profiles of patients with mild cognitive impairment: comparison of two prospective cohort studies. BMJ Open 2012;2(2):e000773. - PMC - PubMed
Kim 2010 {published data only}
    1. Kim SK, Seo SW, Yoon DS, Chin J, Lee BH, Cheong HK, et al. Comparison of neuropsychological and FDG‐PET findings between early‐ versus late‐onset mild cognitive impairment: A five‐year longitudinal study. Dementia and Geriatric Cognitive Disorders 2010;29(3):213‐23. - PubMed
Landau 2011 {published data only}
    1. Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, Weiner MW, Jagust WJ, the Alzheimer's Disease Neuroimaging Initiative. Associations between cognitive, functional, and FDG‐PET measures of decline in AD and MC. Neurobiology of Aging 2011;32(7):1207‐18. - PMC - PubMed
Landau 2012 {published data only}
    1. Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, at al, Alzheimer's Disease Neuroimaging Initiative. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Annals of Neurology 2012;72(4):578‐86. - PMC - PubMed
Lee 2011 {published data only}
    1. Lee DY, Choo LLH, Seo EH, Sohn BK, Park JH, Kim JW, et al. Combination of cerebral metabolic and cognitive information as a better predictor of the conversion to Alzheimer's disease in mild cognitive impairment: A two‐year follow‐up study. Alzheimer's & Dementia 2011;7(4 Supplement):S29.
Lo 2011 {published data only}
    1. Lo RY, Hubbard AlE, Shaw LM, Trojanowski JQ, Petersen RC, Aisen PS. Longitudinal change of biomarkers in cognitive decline. Archives of Neurology 2011;68(10):1257‐66. - PMC - PubMed
Lo 2012 {published data only}
    1. Lo RY, Jagust W. Vascular burden and Alzheimer disease pathologic progression. Neurology 2012;79(13):1349‐55. - PMC - PubMed
Lorenzi 2010 {published data only}
    1. Lorenzi M, Donohue M, Paternico D, Scarpazza C, Ostrowictzki S, Blin O, et al. Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment. Neurobiology 2010;31(8):1443‐51. - PubMed
Lucidi 2012 {published data only}
    1. Lucidi G, Marini S, Nacmias B, Berti V, Bessi V, Bracco L et al . Journal of Alzheimer's Disease Conference: 7th Congresso Sindem: Italian Association for the Study of Dementia Linked to the Italian Neurological Society, SIN Naples Italy. Multidisciplinary approach to MCI help to evaluate risk of conversion in AD. Journal of Alzheimer's Disease Conference: 7th Congresso Sindem: Italian Association for the Study of Dementia Linked to the Italian Neurological Society, SIN Naples Italy. 2012:(var.pagings).
Morbelli 2010 {published data only}
    1. Morbelli S, Piccardo A, Villavecchia G, Dessi B, Brugnolo A, Piccini A, et al. Mapping brain morphological and functional conversion patterns in amnestic MCI: a voxel‐based MRI and FDG‐PET study. European Journal of Nuclear Medicine and Molecular Imaging 2010;37(1):36‐45. [1619‐7070] - PubMed
Morbelli 2012 {published data only}
    1. Morbelli S, Drzezga A, Perneczky R, Frisoni GB, Caroli A, Berckel BNM, et al. Resting metabolic connectivity in prodromal Alzheimer's disease. A European Alzheimer Disease Consortium (EADC) project. Neurobiology of Aging 2012;33(11):2533‐50. - PubMed
Pagani 2010 {published data only}
    1. Pagani M, Dessi B, Morbelli S, Brugnolo A, Salmaso D, Piccini A. MCI patients declining and not‐declining at mid‐term follow‐up: FDG‐PET findings. Current Alzheimer Research 2010;7(4):287‐94. - PubMed
Small 1995 {published data only}
    1. Small GW, Rue A, Komo S, Kaplan A, Mandelkern MA. Predictors of cognitive change in middle‐aged and older adults with memory loss. American Journal of Psychiatry 1995;152(12):1757‐64. - PubMed
Torosyan 2011 {published data only}
    1. Torosyan N, Mason K, Dahlbom M, Silverman DH. Predictive value of FDG‐PET scans for conversion from mild cognitive impairment to dementia by subjects participating in the Alzheimer’s Disease Neuroimaging Initiative study, using a metabolic index generated with clinically routine software. Molecular Imaging and Biology Conference: 2011 World Molecular Imaging Congres, San Diego, CA United States. Conference Publication. 2011.
Walhovd 2010 {published data only}
    1. Walhovd KB, Fjell AM, Brewer J, McEvoy LK, Fennema‐Notestine C, Hagler DJ, et al. Combining MR imaging, positron‐emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. AJNR: American Journal of Neuroradiology 2010;31(2):347‐54. - PMC - PubMed
Zhang 2012 {published data only}
    1. Zhang D, Shen D. Predicting future clinical changes of MCI patients using longitudinal and multimodal biomarkers. PLoS One 2012;7(3):e33182. - PMC - PubMed

Additional references

Albert 2011
    1. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging‐Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia 2011;7(3):270‐9. [1552‐5260] - PMC - PubMed
APA 1987
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐III‐R). 3rd Edition. Washington DC: American Psychiatric Association, 1987.
APA 1994
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐IV‐TR). 4th Edition. Washington DC: American Psychiatric Association, 1994.
Ballard 2011
    1. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet 2011;377(9770):1019‐31. [PUBMED: 21371747] - PubMed
Bartenstein 1997
    1. Bartenstein P, Minoshima S, Hirsch C, Buch K, Willoch F, Mösch D, et al. Quantitative assessment of cerebral blood flow in patients with Alzheimer’s disease by SPECT. Journal of Nuclear Medicine 1997;38(7):1095–101. - PubMed
Bartenstein 2002
    1. Bartenstein P, Asenbaum S, Catafau A, Halldin C, Pilowski L, Pupi A, et al. European Association of Nuclear Medicine procedure guidelines for brain imaging using [18F]FDG. European Journal of Nuclear Medicine and Molecular Imaging 2002;29(10):BP43–8. - PubMed
Beynon 2013
    1. Beynon R, Leeflang MM, McDonald S, Eisinga A, Mitchell RL, Whiting P, et al. Search strategies to identify diagnostic accuracy studies in MEDLINE and EMBASE. Cochrane Database of Systematic Reviews 2013, Issue 9. [DOI: 10.1002/14651858.MR000022.pub3] - DOI - PMC - PubMed
Birks 2006
    1. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD005593] - DOI - PMC - PubMed
Bohnen 2012
    1. Bohnen NI, Djang DSW, Herholz K, Anzai Y, Minoshima S. Effectiveness and safety of 18F‐FDG PET in the evaluation of dementia: a review of the recent literature. Journal of Nuclear Medicine 2012;53(1):59‐71. - PubMed
Bossuyt 2004
    1. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Family Practice 2004;21(1):4‐10. [0263‐2136] - PubMed
Bossuyt 2008
    1. Bossuyt PM, Leeflang MM. Developing criteria for including studies. Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy. Chapter 6. Version 0.4.srdta.cochrane.org/sites/srdta.cochrane.org/files/uploads/Chapter06‐Incl... 2008.
Boxer 2005
    1. Boxer AL, Miller BL. Clinical features of frontotemporal dementia. Alzheimer Disease and Associated Disorders 2005; Vol. 19, issue Suppl 1:S3‐6. [0893‐0341] - PubMed
Braak 1991
    1. Braak H, Braak E. Neuropathological stageing of Alzheimer‐related changes. Acta Neuropathologica 1991; Vol. 82, issue 4:239‐59. [0001‐6322] - PubMed
Bruscoli 2004
    1. Bruscoli M, Lovestone S. Is MCI really just early dementia? A systematic review of conversion studies. International Psychogeriatrics 2004; Vol. 16, issue 2:129‐40. [1041‐6102] - PubMed
Brück 2013
    1. Brück A, Virta JR, Koivunen J, Koikkalainen J, Scheinin NM, Helenius H, et al. [11C]PIB, [18F]FDG and MR imaging in patients with mild cognitive impairment. European Journal of Nuclear Medicine and Molecular Imaging 2013;40(10):1567‐72. - PubMed
Catana 2012
    1. Catana C, Drzezga A, Heiss WD, Rosen BR. PET/MRI for neurologic applications. Journal of Nuclear Medicine 2012;53(12):1916‐25. - PMC - PubMed
Crook 1986
    1. Crook T, Bartus RT, Ferris SH, Whitehouse P, Cohen GD, Gershon S. Report of a National Institute of Mental Health Work Group: Age associated memory impairment: proposed diagnostic criteria and measures of clinical change. Developmental Neuropsychology 1986;2:261‐76.
Del Sole 2008
    1. Sole A, Clerici F, Chiti A, Lecchi M, Mariani C, Magiore L, et al. Individual cerebral metabolic deficits in Alzheimer’s disease and amnestic mild cognitive impairment: an FDG‐PET study. European Journal of Nuclear Medicine and Molecular Imaging 2008;35(7):1357‐66. - PubMed
Drzezga 1999
    1. Drzezga A, Arnold S, Minoshima S, Noachtar S, Szecsi J, Winkler P, et al. 18F‐FDG PET studies in patients with extratemporal and temporal epilepsy: evaluation of an observer‐independent analysis. Journal of Nuclear Medicine 1999;40(5):737–46.. - PubMed
Duara 1986
    1. Duara R, Grady C, Haxby J, Sundaram M, Cutler N, Heston L, et al. Positron emission tomography in Alzheimer's disease. Neurology 1986; Vol. 36, issue 7:879‐87. [0028‐3878] - PubMed
Dubois 2007
    1. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger‐Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS‐ADRDA criteria. Lancet. Neurology 2007;6(8):734‐46. - PubMed
Dubois 2010
    1. Dubois B, Feldman HH, Jacova C, Cummings JL, DeKosky ST, Barberger‐Gateau P, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet. Neurology 2010;9(11):1118‐27. [1474‐4422] - PubMed
Fellgiebel 2004
    1. Fellgiebel A, Siessmeier T, Scheurich A, Winterer G, Bartenstein P, Schmidt LG, at al. Association of elevated phospho‐tau levels with Alzheimer‐typical 18F‐Fluoro‐2‐deoxy‐D‐glucose positron emission tomography findings in patients with mild cognitive impairment. Biological Psychiatry 2004;56(4):279‐83. - PubMed
Ferri 2005
    1. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; Vol. 366, issue 9503:2112‐7. [0140‐6736] - PMC - PubMed
Frisoni 2013
    1. Frisoni GB, Bocchetta M, Chételat G, Rabinovici GD, Leon MJ, Kaye J, et al. Imaging markers for Alzheimer disease: which vs how. Neurology 2013;81(5):487‐500. [DOI: 10.1212/WNL.0b013e31829d86e8] - DOI - PMC - PubMed
Geslani 2005
    1. Geslani DM, Tierney MC, Herrmann N, Szalai JP. Mild cognitive impairment: an operational definition and its conversion rate to Alzheimer’s disease. Dementia and Geriatric Cognitive Disorders 2005; Vol. 19, issue 5‐6:383‐9. [1420‐8008] - PubMed
Hampel 2010
    1. Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, et al. Biomarkers for Alzheimer’s disease: academic, industry and regulatory perspectives. National Reviews. Drug Discovery 2010;9(7):560‐74. - PubMed
Haxby 1986
    1. Haxby JV, Grady CL, Duara R, Schlageter N, Berg G, Rapoport SI. Neocortical metabolic abnormalities precede non memory cognitive defects in early Alzheimer's‐type dementia. Archives of Neurology 1986; Vol. 43, issue 9:882. - PubMed
Herholz 1999
    1. Herholz K, Nordberg A, Salmon E, Perani D, Kessler J, Mielke R, et al. Impairment of neocortical metabolism predicts progression in Alzheimer’s disease. Dementia and Geriatric Cognitive Disorders 1999;10(6):494–504. - PubMed
Herholz 2002
    1. Herholz K, Salmon E, Perani D, Baron J, Holthoff V, Frölich L, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. NeuroImage 2002; Vol. 17, issue 1:302‐16. [1053‐8119] - PubMed
Hoffman 2000
    1. Hoffman JM, Welsh‐Bohmer KA, Hanson M, Crain B, Hulette C, Earl N, et al. FDG PET imaging in patients with pathologically verified dementia. Journal of Nuclear Medicine 2000;41(11):1920‐8. - PubMed
ICD‐10 2010
    1. World Health Organization. Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD‐10). available fromapps.who.int/classifications/icd10/browse/2010/en.International (accessed 16th December 2012) 2010.
ICD‐9 2006
    1. World Health Organization. Statistical Classification of Diseases and Related Health Problems 9th Revision (ICD‐9). 6th Edition. Vol. Hospital edition, vols. 1, 2, 3, Los Angeles, CA: Practice Management Information Corporation (PMIC), 2006.
Ishii 2001
    1. Ishii K, Willoch F, Minoshima S, Drzezga A, Ficaro EP, Cross DJ, et al. Statistical brain mapping of 18F‐FDG PETin Alzheimer’s disease: validation of anatomic standardization for atrophied brains. Journla of Nuclear Medicine 2001;42(4):548 –57. - PubMed
Jagust 2010
    1. Jagust WJ, Bandy D, Chen K, Foster NL, Landau SM, Mathis CA, et al. The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimer's & Dementia 2010;6:221‐9. - PMC - PubMed
Jelic 1999
    1. Jelic V, Wahlund LO, Almkvist O, Johansson SE, Shigeta M, Winblad B, Nordberg A. Diagnostic accuracies of quantitative EEG and PET in mild Alzheimer’s disease. Alzheimer's Reports 1999;2(5):291‐8.
Knopman 2005
    1. Knopman DS, Boeve BF, Parisi JE, Dickson DW, Smith GE, Ivnik RJ. Antemortem diagnosis of frontotemporal lobar degeneration. Annals of Neurology 2005;57(4):480–8. - PubMed
Knottnerus 2002
    1. Knottnerus JA, Weel C, Muris JWM. Evaluation of diagnostic procedures. BMJ 2002; Vol. 324, issue 7335:477‐80. [0959‐8138] - PMC - PubMed
Laforce 2010
    1. Laforce R Jr, Buteau JP, Paquet N, Verret L, Houde M, Bouchard RW. The value of PET in mild cognitive impairment, typical and atypical/unclear dementias: a retrospective memory clinic study. American Journal of Alzheimer's Disease and Other Dementias 2010;25(4):324‐32. - PMC - PubMed
Leeflang 2008
    1. Leeflang MMG, Deeks JJ, Gatsonis C, Bossuyt PMM. Systematic reviews of diagnostic test accuracy. Annals of Internal Medicine 2008; Vol. 149, issue 12:889. - PMC - PubMed
Lucignani 2006
    1. Lucignani G, Frost JF. Neurochemical imaging with emission tomography: Clinical applications.link.springer.com/chapter/10.1007/3‐540‐30005‐8_2#page‐1Diagnostic nuclear medicine (accessed January 12 2015) 2006.
Lund Manchester 1994
    1. The Lund and Manchester Groups. Clinical and neuropathological criteria for frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry 1994;57(4):416‐8. - PMC - PubMed
Matthews 2008
    1. Matthews FE, Stephan B, McKeith IG, Bond J, Brayne C. Two‐year progression from mild cognitive impairment to dementia: to what extent do different definitions agree?. Journal of the American Geriatrics Society 2008; Vol. 56, issue 8:1424‐33. [1532‐5415] - PubMed
Mattsson 2009
    1. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009;302(4):385‐93. - PubMed
McKeith 1996
    1. McKeith I, Galasko D, Kosaka K, Perry E, Dickson D, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB) Report of the consortium on DLB international workshop. Neurology 1996; Vol. 47, issue 5:1113‐24. [0028‐3878] - PubMed
McKeith 2006
    1. McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. Journal of Alzheimer's Disease 2006; Vol. 9, issue 3 Suppl:417‐23. [1387‐2877] - PubMed
McKhann 1984
    1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34(7):939‐44. [0028‐3878] - PubMed
McKhann 2011
    1. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging‐Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia 2011;7(3):263‐9. [1552‐5260] - PMC - PubMed
McShane 2006
    1. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD003154.pub5] - DOI - PubMed
Minoshima 1995
    1. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer's disease using three‐dimensional stereotactic surface projections of fluorine‐18‐FDG PET. Journal of Nuclear Medicine 1995;36(7):1238‐48. - PubMed
Morris 1993
    1. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology; Neurology 1993;43(11):2412‐4. [1526‐632X] - PubMed
Morris 2001
    1. Morris JC, Price JL. Pathologic correlates of non demented aging, mild cognitive impairment, and early‐stage Alzheimer’s disease. Journal of Molecular Neuroscience 2001; Vol. 17, issue 2:101‐18. [0895‐8696] - PubMed
Mosconi 2009
    1. Mosconi L. FDG PET in the evaluation of mild cognitive impairment and early dementia. In: Silverman D editor(s). PET in the Evaluation of Alzheimer's Disease and Related Disorders. Springer, 2009:49‐65. [0387764194]
Moulin‐Romsee 2005
    1. Moulin‐Romsee G, Maes A, Silverman D, Mortelmans L, Laere K. Cost‐effectiveness of 18F‐fluorodeoxyglucose positron emission tomography in the assessment of early dementia from a Belgian and European perspective. European Journal of Neurology 2005;12(4):254‐63. - PubMed
NAO 2007
    1. National Audit Office. Improving Services and Support for People with Dementia.www.nao.org.uk/wp‐content/uploads/2007/07/0607604.pdf 2007.
Neary 1998
    1. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998; Vol. 51, issue 6:1546‐54. [0028‐3878] - PubMed
Nitrini 2000
    1. Nitrini R, Buchpiguel C, Caramelli P, Bahia V, Mathias S, Nascimento C, et al. SPECT in Alzheimer's disease: features associated with bilateral parietotemporal hypoperfusion. Acta Neurologica Scandinavica 2000; Vol. 101, issue 3:172‐6. [1600‐0404] - PubMed
Oddo 2004
    1. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004; Vol. 43, issue 3:321‐32. - PubMed
Okello 2009
    1. Okello A, Edison P, Archer H, Turkheimer F, Kennedy J, Bullock R, et al. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology 2009; Vol. 72, issue 1:56‐62. [0028‐3878] - PMC - PubMed
Patterson 2010
    1. Patterson JC, Lilien DL, Takalkar A, Pinkston JB. Early detection of brain pathology suggestive of early AD using objective evaluation of FDG‐PET scans. International Journal of Alzheimer's Disease 2010; Vol. 2011:ii. 946590. [DOI: 10.4061/2011/946590] - DOI - PMC - PubMed
Petersen 1999
    1. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology 1999; Vol. 56, issue 3:303‐8. - PubMed
Petersen 2001
    1. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Archives of Neurology 2001; Vol. 58, issue 12:1985‐92. - PubMed
Petersen 2003
    1. Petersen RC. Conceptual overview. In: Petersen RC editor(s). Mild Cognitive Impairment: Aging to Alzheimer’s Disease. New York:: Oxford University Press, 2003:1‐14.
Petersen 2004
    1. Petersen RC. Mild cognitive impairment as a diagnostic entity. Journal of Internal Medicine 2004; Vol. 256, issue 3:183‐94. [1365‐2796] - PubMed
Petersen 2009
    1. Petersen RC, Roberts RO, Knopman DS, Boeve BF, Geda YE, Ivnik RJ, et al. Mild cognitive impairment: ten years later. Archives of Neurology 2009; Vol. 66, issue 12:1447‐55. - PMC - PubMed
Petersen 2010
    1. Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, et al. Alzheimer’s Disease Neuroimaging Initiative (ADNI): Clinical characterization. Neurology 2010;74(3):201‐9. - PMC - PubMed
Quinn 2014
    1. Quinn TJ, Fearon P, Noel‐Storr AH, Young C, McShane R, Stott DJ. Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within community dwelling populations. Cochrane Database of Systematic Reviews 2014, Issue 4. [DOI: 10.1002/14651858.CD010079] - DOI - PubMed
Reisberg 1982
    1. Reisberg B, Ferris SH, Leon MJ. Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. American Journal of Psychiatry 1982;139(9):1136‐9. - PubMed
Román 1993
    1. Román GC, Tatemichi TK, Erkinjuntti T, Cummings J, Masdeu J, Garcia JH, et al. Vascular dementia diagnostic criteria for research studies: Report of the NINDS‐AIREN International Workshop. Neurology 1993; Vol. 43, issue 2:250‐60. [0028‐3878] - PubMed
Rosen 1984
    1. Rosen WG, Mohs RC, Davis KL. A new rating scale forAlzheimer’s disease. American Journal of Psychiatry 1984;141(11):1356–64. - PubMed
Rutter 2001
    1. Rutter CM, Gatsonis CA. A hierarchical regression approach to meta‐analysis of diagnostic test accuracy evaluations. Statistics in Medicine 2001; Vol. 20, issue 19:2865‐84. [1097‐0258] - PubMed
Schroeter 2009
    1. Schroeter ML, Stein T, Maslowski N, Neumann J. Neural correlates of Alzheimer's disease and mild cognitive impairment: a systematic and quantitative meta‐analysis involving 1351 patients. NeuroImage 2009; Vol. 47, issue 4:1196‐206. [1053‐8119] - PMC - PubMed
Silverman 2002
    1. Silverman DH, Gambhir SS, Huang HW, Schwimmer J, Kim S, Small GW, et al. Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: a comparison of predicted costs and benefits. Journal of Nuclear Medicine 2002;43(2):253‐66. - PubMed
Silverman 2001
    1. Silverman DH, Small GW, Chang CY, Lu CS, Kung De Aburto MA, Chen W, et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long‐term outcome. JAMA 2001;286(17):2120‐7. - PubMed
Silverman 2009
    1. Silverman DHS. Clinical interpretation of brain PET scans: performing visual assessments, providing quantifying data, and generating integrated reports. In: Silverman DHS editor(s). PET in the Evaluation of Alzheimer’s Disease and Related Disorders. New York: Springer, 2009:33‐49.
Sperling 2011
    1. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia 2011; Vol. 7, issue 3:280‐92. [1552‐5260] - PMC - PubMed
Varrone 2009
    1. Varrone A, Asenbaum S, Vander Borght V, Booij J, Nobili F, Någren K, et al. EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. European Journal of Nuclear Medicine and Molecular Imaging 2009;36(12):2103‐10. - PubMed
Visser 2006
    1. Visser PJ, Kester A, Jolles J, Verhey F. Ten‐year risk of dementia in subjects with mild cognitive impairment. Neurology 2006; Vol. 67, issue 7:1201‐7. [0028‐3878] - PubMed
Waxman 2009
    1. Waxman A, Herholz K, Lewis D, Herscovitch P, Minoshima S, Ichise M, et al. Society of Nuclear Medicine procedure guideline for FDG PET brain imaging.interactive.snm.org/docs/FDG_brain_perfusion_V0%203%20(10‐1)%20Final.pdf (accessed 12th January 2015) 2009.
Whiting 2011
    1. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al: QUADAS‐2 Group. QUADAS‐2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal Medicine 2011;155(8):529‐36. - PubMed
Winblad 2004
    1. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, et al. Mild cognitive impairment–beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. Journal of Internal Medicine 2004; Vol. 256, issue 3:240‐6. [1365‐2796] - PubMed

References to other published versions of this review

Vacante 2013
    1. Vacante M, Smailagic N, Sachpekidis C, Hyde C, Martin S, Ukoumunne O. The accuracy of 18FDG‐PET in the early diagnosis of Alzheimer’s disease dementia and other dementias in people with MCI. Cochrane Database of Systematic Reviews 2013, Issue 7. [DOI: 10.1002/14651858.CD010632] - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full text links
Wiley full text link Wiley Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp